Phase II study of 9-10 anthracene-dicarboxaldehyde bis(4,5-dihydro-1H-imidazol-2-yl) hydrazone dihydrochloride (CL216,942; ADAH) in patients with advanced colorectal carcinoma.
作者信息
Rubin J, Kvols L K, Moertel C G, Jones A R, Hahn R G, O'Connell M J
出版信息
Am J Clin Oncol. 1983 Aug;6(4):477-9. doi: 10.1097/00000421-198308000-00015.
Abstract
A phase II study of ADAH was conducted in thirty patients with biopsy-prove metastatic or recurrent colorectal carcinoma in order to define its benefits and toxicity. Doses were adjusted by leukocyte nadirs. No patients met the criteria for complete or partial response.
摘要
Zotero 插件